Galderma

GALD · SIX · Switzerland

Public Market Listing

GALDSIX

SIX primary exchange listing

Live quotes, historical charts, and market capitalization for Galderma are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
nemolizumab(Nemluvio)
Approved
IL-31 receptor AMonoclonal antibody
Atopic DermatitisPrurigo Nodularis

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
nemolizumab · NemluvioPhase 2Chronic Pruritus of Unknown Origin
Est. primary completion 2026-12 · NCT07074977 · CT.gov ↗
What to watch
2027 (1)
October 2027 (1)
nemolizumab · NemluvioPhase 3Atopic Dermatitis
Est. primary completion 2027-10-28 · NCT07762833 · CT.gov ↗
What to watch
2028 (2)
May 2028 (1)
nemolizumab · NemluvioPhase 2Systemic Sclerosis
Est. primary completion 2028-05-28 · NCT07047690 · CT.gov ↗
What to watch
July 2028 (1)
nemolizumab · NemluvioPhase 2Moderate-to-Severe Atopic Dermatitis
Est. primary completion 2028-07-15 · NCT07660835 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-H1$3.1B———report ↗